ozempic hims - Search News

Hims & Hers Health, Novo Nordisk

Hosted on MSN · 22h

Stock of the Day: Hims & Hers plunges 27% after saying it will stop selling its Ozempic competitor

With Hims & Hers' main source of growth set to be extinguished, Citi analysts said its full-year guidance appeared "aspirational."

MarketWatch on MSN · 1d

Novo Nordisk shares are rallying as Hims & Hers’ stock falters. An Ozempic alternative won’t be available for long.

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer.

24/7 Wall St. on MSN · 2d

HIMS is Out. Is Novo Nordisk or Eli Lilly the Better GLP-1 Buy?

The Food & Drug Administration announced last week that the Ozempic and Wegovy shortage for Novo Nordisk‘s (NYSE:NVO) was over. It said the Danish pharmaceutical had sufficient supply of its semaglutide therapies to meet current and future,

Hims & Hers Health, co and US FDA

Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Investopedia on MSN · 4d

Hims & Hers Stock Drops as FDA Says Ozempic and Wegovy No Longer in Short Supply

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in Eli Lilly’s Wegovy and Novo Nordisk’s Ozempic has been resolved.

Drug compounders sue US FDA over removal of Wegovy, Ozempic from shortage list

Drug compounders sued the U.S. Food and Drug Administration on Monday over its decision last week to remove Novo Nordisk's weight-loss and diabetes treatments Wegovy and Ozempic from its shortage list,

23hon MSN

Hims & Hers can't sell off-brand Ozempic forever. But it can still sell these weight loss drugs

Hims & Hers (HIMS) made a killing last year selling an off-brand version of Ozempic, but with the drug’s shortage now over, ...

1don MSN

Hims is officially phasing out its copycat weight-loss drugs, and the company's stock tumbled — again

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

ConsumerAffairs1d

Hims & Hers withdraws from Wegovy, Ozempic market

Hims & Hers is stopping its sales of an alternative to blockbuster weight-loss drugs Wegovy and Ozempic. That follows the U.S ...

2hon MSN

Why Hims & Hers Health, Inc. (HIMS) Went Down on Tuesday

We recently published an article titled Two of 10 Worst-Performing Stocks Fall to All-Time Lows on Tuesday. In this article, ...

Hims and Hers likely to stop selling cheaper versions of GLP-1 medications

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

1don MSN

Hims & Hers shares tumble after company misses on margin, says may stop selling some weight loss drugs

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

1d

Hims & Hers offers upbeat forecast, but stock slides after hours

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...

Money Morning4d

Ozempic Maker Is Ready to Fight Back Against Hims & Hers

Semaglutide is a glucagon-like peptide-1 (GLP-1) that helps regulate blood sugar levels. Because of outsized demand for ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results